Compile Data Set for Download or QSAR
Report error Found 516 Enz. Inhib. hit(s) with all data for entry = 8704
TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413625(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50: 0.260nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413725(N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetr...)
Affinity DataIC50: 0.260nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413721(4-{[(2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl...)
Affinity DataIC50: 0.310nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413626(4-[(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.340nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413727((2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-...)
Affinity DataIC50: 0.340nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413719(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413745(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413610(4-{[(2S)-2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]...)
Affinity DataIC50: 0.400nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413722(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.460nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413726(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50: 0.5nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413652(4-{[(2S)-4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazo...)
Affinity DataIC50: 0.530nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413720(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.550nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413777(US10421742, Example 170 | N-(Quinoxalin-6-yl)-(2S)...)
Affinity DataIC50: 0.550nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413724(N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-...)
Affinity DataIC50: 0.560nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413725(N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetr...)
Affinity DataIC50: 0.570nMAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413746(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50: 0.590nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413773(US10421742, Example 166 | 4-({2-[4-{5-Chloro-2-[4-...)
Affinity DataIC50: 0.620nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413847(US10421742, Example 240 | 4-{[(2S)-2-{4-[5-Chloro-...)
Affinity DataIC50: 0.640nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413793(US10421742, Example 186 | 2-{4-[5-Chloro-2-(4-chlo...)
Affinity DataIC50: 0.650nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413797(US10421742, Example 190 | 4-[({4-[5-Chloro-2-(1H-t...)
Affinity DataIC50: 0.650nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413851(US10421742, Example 244 | (2S)-2-{4-[5-Chloro-2-(4...)
Affinity DataIC50: 0.650nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413723(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.660nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413633(4-[(2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]...)
Affinity DataIC50: 0.700nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413770(US10421742, Example 163 | N-(Quinoxalin-6-yl)-(2S)...)
Affinity DataIC50: 0.700nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413748(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.710nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413749(4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-...)
Affinity DataIC50: 0.710nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413743(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.720nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413796(US10421742, Example 189 | N-(Quinoxalin-6-yl)-2-{4...)
Affinity DataIC50: 0.730nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413858(US10421742, Example 251 | 4-({(2S)-2-[4-{5-Chloro-...)
Affinity DataIC50: 0.740nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413792(US10421742, Example 185 | N-(Quinoxalin-6-yl)-2-{4...)
Affinity DataIC50: 0.75nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413747(N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-...)
Affinity DataIC50: 0.760nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413775(US10421742, Example 168 | (2S)-2-{4-[5-Chloro-2-(4...)
Affinity DataIC50: 0.780nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413817(US10421742, Example 210 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.780nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413727((2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-...)
Affinity DataIC50: 0.780nMAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413840(US10421742, Example 233 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.790nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413861(US10421742, Example 254 | 2-{4-[5-Chloro-2-(4-chlo...)
Affinity DataIC50: 0.810nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413779(US10421742, Example 172 | 2-{4-[5-Chloro-2-(1H-tet...)
Affinity DataIC50: 0.820nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413641(US10421742, Example 35 | 4-[(2-{4-[5-Chloro-2-(4,5...)
Affinity DataIC50: 0.830nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413737((2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1...)
Affinity DataIC50: 0.840nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413744(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.840nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413864(US10421742, Example 257 | (2S)-2-{4-[5-Chloro-2-(4...)
Affinity DataIC50: 0.850nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413772(US10421742, Example 165 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.860nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413850(US10421742, Example 243 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.870nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413844(US10421742, Example 237 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.890nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413846(US10421742, Example 239 | 4-({2-[4-{5-Chloro-2-[4-...)
Affinity DataIC50: 0.890nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413849(US10421742, Example 242 | 4-{[(2S)-2-{4-[5-Chloro-...)
Affinity DataIC50: 0.890nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413696(4-[(2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-y...)
Affinity DataIC50: 0.920nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413842(US10421742, Example 235 | 4-({(2S)-2-[4-{5-Chloro-...)
Affinity DataIC50: 0.920nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413706(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)p...)
Affinity DataIC50: 0.960nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 516 total ) | Next | Last >>
Jump to: